 Amrut Ambardekar
Concepts (417)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 36 | 2023 | 493 | 8.520 |
Why?
| | Heart Failure | 50 | 2023 | 1955 | 6.680 |
Why?
| | Heart Transplantation | 23 | 2023 | 652 | 5.140 |
Why?
| | Amyloidosis | 4 | 2023 | 36 | 1.850 |
Why?
| | Heart Ventricles | 9 | 2020 | 710 | 1.660 |
Why?
| | Cardiomyopathies | 7 | 2023 | 296 | 1.470 |
Why?
| | Cardiomyopathy, Dilated | 9 | 2020 | 348 | 1.160 |
Why?
| | Ventricular Dysfunction, Left | 8 | 2023 | 361 | 1.090 |
Why?
| | Myocardium | 10 | 2023 | 906 | 0.980 |
Why?
| | Arrhythmias, Cardiac | 6 | 2022 | 281 | 0.900 |
Why?
| | Myocytes, Cardiac | 11 | 2023 | 447 | 0.880 |
Why?
| | Humans | 97 | 2023 | 113531 | 0.870 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2020 | 216 | 0.870 |
Why?
| | Defibrillators, Implantable | 4 | 2020 | 288 | 0.830 |
Why?
| | Rejuvenation | 1 | 2022 | 14 | 0.800 |
Why?
| | Transplant Recipients | 4 | 2021 | 130 | 0.790 |
Why?
| | Assisted Circulation | 2 | 2021 | 25 | 0.780 |
Why?
| | Fibrosis | 5 | 2022 | 452 | 0.780 |
Why?
| | Echocardiography | 7 | 2017 | 563 | 0.770 |
Why?
| | Hemodynamics | 7 | 2023 | 996 | 0.770 |
Why?
| | Aortic Valve Insufficiency | 1 | 2022 | 45 | 0.770 |
Why?
| | Vascular Stiffness | 2 | 2017 | 403 | 0.760 |
Why?
| | Immunosuppressive Agents | 5 | 2021 | 633 | 0.730 |
Why?
| | Stroke Volume | 8 | 2023 | 510 | 0.720 |
Why?
| | Calcineurin Inhibitors | 1 | 2021 | 57 | 0.710 |
Why?
| | Giant Cells | 1 | 2020 | 21 | 0.710 |
Why?
| | Arteries | 1 | 2022 | 244 | 0.700 |
Why?
| | Aortic Diseases | 1 | 2021 | 105 | 0.700 |
Why?
| | Ventricular Function, Left | 7 | 2023 | 469 | 0.700 |
Why?
| | Heart Neoplasms | 1 | 2020 | 49 | 0.680 |
Why?
| | Sarcoma, Kaposi | 1 | 2020 | 68 | 0.680 |
Why?
| | Middle Aged | 33 | 2022 | 26552 | 0.660 |
Why?
| | Ventricular Function, Right | 4 | 2020 | 251 | 0.660 |
Why?
| | Myocarditis | 1 | 2020 | 92 | 0.650 |
Why?
| | Coronary Vessels | 2 | 2018 | 231 | 0.650 |
Why?
| | Graft Rejection | 3 | 2021 | 508 | 0.630 |
Why?
| | Brugada Syndrome | 2 | 2009 | 9 | 0.610 |
Why?
| | Myocardial Contraction | 4 | 2020 | 314 | 0.610 |
Why?
| | Bariatric Surgery | 1 | 2021 | 159 | 0.610 |
Why?
| | Heart | 6 | 2023 | 609 | 0.600 |
Why?
| | Extracellular Matrix | 1 | 2021 | 433 | 0.590 |
Why?
| | Male | 45 | 2022 | 55112 | 0.590 |
Why?
| | Ventricular Remodeling | 3 | 2021 | 221 | 0.560 |
Why?
| | Myocardial Ischemia | 4 | 2019 | 237 | 0.540 |
Why?
| | Female | 45 | 2022 | 59115 | 0.540 |
Why?
| | Thrombosis | 2 | 2016 | 293 | 0.510 |
Why?
| | Heart Rate | 2 | 2021 | 705 | 0.500 |
Why?
| | Cryosurgery | 1 | 2016 | 51 | 0.500 |
Why?
| | Surgical Procedures, Operative | 1 | 2017 | 208 | 0.470 |
Why?
| | Blood Pressure | 5 | 2022 | 1521 | 0.470 |
Why?
| | Tachycardia, Ventricular | 1 | 2016 | 153 | 0.450 |
Why?
| | Aged | 19 | 2022 | 18944 | 0.450 |
Why?
| | Electrocardiography | 4 | 2020 | 558 | 0.450 |
Why?
| | Marijuana Abuse | 1 | 2016 | 207 | 0.440 |
Why?
| | Treatment Outcome | 12 | 2021 | 9006 | 0.420 |
Why?
| | Physician-Patient Relations | 1 | 2017 | 459 | 0.420 |
Why?
| | Aorta, Thoracic | 1 | 2015 | 248 | 0.410 |
Why?
| | Myofibrils | 3 | 2022 | 44 | 0.400 |
Why?
| | Adult | 21 | 2023 | 30245 | 0.400 |
Why?
| | Patient-Centered Care | 2 | 2021 | 470 | 0.400 |
Why?
| | Guideline Adherence | 3 | 2011 | 489 | 0.380 |
Why?
| | Patient Compliance | 2 | 2017 | 523 | 0.360 |
Why?
| | Recovery of Function | 2 | 2011 | 567 | 0.350 |
Why?
| | Cardiology | 2 | 2023 | 260 | 0.350 |
Why?
| | Risk Assessment | 6 | 2021 | 2953 | 0.340 |
Why?
| | Calcium | 4 | 2023 | 1086 | 0.340 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2088 | 0.340 |
Why?
| | Cardiac Tamponade | 1 | 2010 | 14 | 0.340 |
Why?
| | RNA, Long Noncoding | 2 | 2022 | 150 | 0.340 |
Why?
| | Cannabis | 1 | 2016 | 382 | 0.340 |
Why?
| | Hospitals, Rural | 1 | 2009 | 31 | 0.330 |
Why?
| | Electric Stimulation Therapy | 1 | 2010 | 54 | 0.330 |
Why?
| | Sarcomeres | 3 | 2022 | 88 | 0.330 |
Why?
| | Baroreflex | 2 | 2021 | 54 | 0.330 |
Why?
| | Automobile Driving | 1 | 2011 | 129 | 0.330 |
Why?
| | Cardiac Output | 3 | 2023 | 139 | 0.330 |
Why?
| | Safety | 1 | 2011 | 297 | 0.320 |
Why?
| | Registries | 6 | 2021 | 1762 | 0.320 |
Why?
| | Hospitals, Urban | 1 | 2009 | 128 | 0.320 |
Why?
| | Cardiac Pacing, Artificial | 1 | 2009 | 78 | 0.320 |
Why?
| | Pulsatile Flow | 2 | 2018 | 54 | 0.310 |
Why?
| | Counseling | 1 | 2011 | 342 | 0.300 |
Why?
| | Vascular Remodeling | 2 | 2021 | 152 | 0.300 |
Why?
| | Length of Stay | 2 | 2009 | 963 | 0.300 |
Why?
| | Mineralocorticoid Receptor Antagonists | 2 | 2023 | 39 | 0.300 |
Why?
| | Mastitis | 1 | 2007 | 4 | 0.290 |
Why?
| | Diagnosis, Differential | 4 | 2019 | 1328 | 0.290 |
Why?
| | Prospective Studies | 10 | 2021 | 6189 | 0.290 |
Why?
| | Puerperal Disorders | 1 | 2007 | 30 | 0.290 |
Why?
| | Retrospective Studies | 13 | 2023 | 12504 | 0.280 |
Why?
| | Coronary Disease | 1 | 2009 | 347 | 0.280 |
Why?
| | Quality Assurance, Health Care | 1 | 2009 | 309 | 0.280 |
Why?
| | Environment | 1 | 2009 | 326 | 0.270 |
Why?
| | Follow-Up Studies | 6 | 2021 | 4384 | 0.270 |
Why?
| | HIV Infections | 1 | 2020 | 2440 | 0.270 |
Why?
| | Diastole | 2 | 2018 | 135 | 0.260 |
Why?
| | Inpatients | 1 | 2009 | 379 | 0.260 |
Why?
| | Troponin I | 2 | 2019 | 67 | 0.250 |
Why?
| | Quality of Health Care | 1 | 2009 | 572 | 0.240 |
Why?
| | Perioperative Care | 2 | 2017 | 127 | 0.230 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2021 | 1856 | 0.210 |
Why?
| | MicroRNAs | 2 | 2022 | 598 | 0.210 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2023 | 10 | 0.210 |
Why?
| | Preoperative Care | 2 | 2017 | 318 | 0.210 |
Why?
| | Patient Transfer | 2 | 2019 | 142 | 0.210 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2023 | 37 | 0.210 |
Why?
| | Quality of Life | 5 | 2023 | 2335 | 0.210 |
Why?
| | Cohort Studies | 6 | 2023 | 4880 | 0.210 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2022 | 30 | 0.200 |
Why?
| | Heart Injuries | 1 | 2023 | 37 | 0.200 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2023 | 76 | 0.200 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 387 | 0.200 |
Why?
| | Metalloproteases | 1 | 2022 | 36 | 0.200 |
Why?
| | Cadherin Related Proteins | 1 | 2022 | 12 | 0.200 |
Why?
| | Matrix Metalloproteinases, Secreted | 1 | 2021 | 10 | 0.190 |
Why?
| | Long Term Adverse Effects | 1 | 2021 | 10 | 0.190 |
Why?
| | ADAMTS4 Protein | 1 | 2021 | 15 | 0.190 |
Why?
| | Succinic Acid | 2 | 2019 | 38 | 0.190 |
Why?
| | Cation Transport Proteins | 1 | 2022 | 123 | 0.190 |
Why?
| | Hypertension | 2 | 2020 | 1051 | 0.190 |
Why?
| | Leukopenia | 1 | 2021 | 27 | 0.190 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 16 | 0.190 |
Why?
| | Cardiovascular System | 1 | 2023 | 124 | 0.190 |
Why?
| | Case-Control Studies | 4 | 2022 | 2993 | 0.190 |
Why?
| | Calcium-Binding Proteins | 1 | 2022 | 201 | 0.180 |
Why?
| | Carrier Proteins | 2 | 2022 | 685 | 0.180 |
Why?
| | Hospitalization | 3 | 2022 | 1765 | 0.180 |
Why?
| | Heart Failure, Systolic | 1 | 2021 | 21 | 0.180 |
Why?
| | Pressoreceptors | 1 | 2021 | 18 | 0.180 |
Why?
| | Myocardial Infarction | 2 | 2023 | 932 | 0.180 |
Why?
| | Alternative Splicing | 1 | 2022 | 184 | 0.180 |
Why?
| | Mycophenolic Acid | 1 | 2021 | 75 | 0.180 |
Why?
| | Muscle Proteins | 1 | 2022 | 206 | 0.180 |
Why?
| | Cell Adhesion | 2 | 2018 | 423 | 0.170 |
Why?
| | Disease Progression | 2 | 2018 | 2364 | 0.170 |
Why?
| | Immunohistochemistry | 2 | 2021 | 1604 | 0.170 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2021 | 121 | 0.170 |
Why?
| | United States | 9 | 2023 | 12137 | 0.170 |
Why?
| | Consensus | 4 | 2023 | 533 | 0.170 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2020 | 95 | 0.160 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2530 | 0.160 |
Why?
| | Terminology as Topic | 1 | 2020 | 185 | 0.160 |
Why?
| | Mice | 11 | 2023 | 14679 | 0.160 |
Why?
| | HIV | 1 | 2020 | 205 | 0.160 |
Why?
| | Longitudinal Studies | 3 | 2016 | 2361 | 0.160 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 248 | 0.160 |
Why?
| | Prognosis | 4 | 2021 | 3318 | 0.160 |
Why?
| | Exercise Test | 4 | 2023 | 546 | 0.160 |
Why?
| | Clinical Decision-Making | 2 | 2020 | 267 | 0.160 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 182 | 0.160 |
Why?
| | Cell Culture Techniques | 1 | 2021 | 337 | 0.150 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2020 | 173 | 0.150 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 222 | 0.150 |
Why?
| | Aortic Valve | 1 | 2022 | 391 | 0.150 |
Why?
| | Filamins | 1 | 2018 | 19 | 0.150 |
Why?
| | Mutation | 2 | 2018 | 3313 | 0.150 |
Why?
| | Mitochondrial Proteins | 1 | 2019 | 212 | 0.150 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 168 | 0.150 |
Why?
| | Pilot Projects | 3 | 2019 | 1356 | 0.150 |
Why?
| | Recurrence | 1 | 2020 | 925 | 0.140 |
Why?
| | Transcriptome | 2 | 2020 | 719 | 0.140 |
Why?
| | Brain | 2 | 2018 | 2309 | 0.140 |
Why?
| | Animals | 14 | 2023 | 31162 | 0.140 |
Why?
| | NAV1.5 Voltage-Gated Sodium Channel | 1 | 2017 | 10 | 0.140 |
Why?
| | Anesthetics | 1 | 2017 | 54 | 0.140 |
Why?
| | Cerebrovascular Circulation | 1 | 2018 | 205 | 0.140 |
Why?
| | PTEN Phosphohydrolase | 1 | 2018 | 140 | 0.140 |
Why?
| | Immunity, Cellular | 1 | 2018 | 246 | 0.140 |
Why?
| | ErbB Receptors | 1 | 2020 | 553 | 0.140 |
Why?
| | Caliciviridae Infections | 1 | 2016 | 17 | 0.130 |
Why?
| | Transition to Adult Care | 1 | 2017 | 60 | 0.130 |
Why?
| | Cell Differentiation | 2 | 2021 | 1681 | 0.130 |
Why?
| | Down-Regulation | 2 | 2016 | 593 | 0.130 |
Why?
| | Self Care | 1 | 2019 | 350 | 0.130 |
Why?
| | Prosthesis Design | 3 | 2014 | 282 | 0.130 |
Why?
| | Polypharmacy | 1 | 2017 | 74 | 0.130 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 922 | 0.130 |
Why?
| | Histone Deacetylases | 1 | 2018 | 194 | 0.130 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 443 | 0.130 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2018 | 235 | 0.130 |
Why?
| | Eligibility Determination | 1 | 2016 | 59 | 0.130 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1510 | 0.130 |
Why?
| | Hypoglycemic Agents | 1 | 2023 | 1006 | 0.130 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2016 | 61 | 0.130 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2018 | 367 | 0.130 |
Why?
| | Antiviral Agents | 1 | 2021 | 635 | 0.130 |
Why?
| | Drug Interactions | 1 | 2017 | 332 | 0.130 |
Why?
| | Nonprescription Drugs | 1 | 2016 | 68 | 0.130 |
Why?
| | Biomarkers | 3 | 2023 | 3389 | 0.120 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 260 | 0.120 |
Why?
| | Phosphorylation | 3 | 2019 | 1537 | 0.120 |
Why?
| | Tacrolimus | 1 | 2016 | 133 | 0.120 |
Why?
| | Hospital Mortality | 2 | 2009 | 780 | 0.120 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 2015 | 45 | 0.120 |
Why?
| | Postoperative Care | 1 | 2017 | 224 | 0.120 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1076 | 0.120 |
Why?
| | Viscosity | 1 | 2015 | 81 | 0.120 |
Why?
| | Health Status | 1 | 2019 | 716 | 0.120 |
Why?
| | Rats | 5 | 2022 | 4829 | 0.120 |
Why?
| | Prescription Drugs | 1 | 2016 | 116 | 0.120 |
Why?
| | Cardiovascular Agents | 2 | 2020 | 125 | 0.120 |
Why?
| | Coronary Artery Disease | 1 | 2020 | 610 | 0.120 |
Why?
| | Partial Thromboplastin Time | 1 | 2014 | 50 | 0.120 |
Why?
| | Elastic Modulus | 1 | 2015 | 116 | 0.120 |
Why?
| | Atherosclerosis | 1 | 2018 | 342 | 0.110 |
Why?
| | Transcription, Genetic | 1 | 2020 | 1282 | 0.110 |
Why?
| | Vaccination | 1 | 2022 | 1198 | 0.110 |
Why?
| | Incidence | 3 | 2019 | 2310 | 0.110 |
Why?
| | Attitude to Health | 1 | 2017 | 398 | 0.110 |
Why?
| | Ambulatory Care | 1 | 2017 | 480 | 0.110 |
Why?
| | Quality Improvement | 1 | 2021 | 951 | 0.110 |
Why?
| | Hip Prosthesis | 1 | 2014 | 32 | 0.110 |
Why?
| | Liver Transplantation | 1 | 2020 | 693 | 0.110 |
Why?
| | Systole | 1 | 2014 | 173 | 0.110 |
Why?
| | Patient Selection | 2 | 2017 | 625 | 0.110 |
Why?
| | Shock, Cardiogenic | 1 | 2014 | 54 | 0.110 |
Why?
| | Time Factors | 4 | 2023 | 6032 | 0.110 |
Why?
| | Young Adult | 6 | 2019 | 10400 | 0.110 |
Why?
| | Patient Education as Topic | 1 | 2017 | 665 | 0.110 |
Why?
| | Prosthesis Failure | 1 | 2014 | 114 | 0.100 |
Why?
| | Blood Coagulation | 1 | 2014 | 200 | 0.100 |
Why?
| | Marijuana Smoking | 1 | 2016 | 223 | 0.100 |
Why?
| | Attitude of Health Personnel | 2 | 2017 | 970 | 0.100 |
Why?
| | Nuclear Proteins | 1 | 2016 | 584 | 0.100 |
Why?
| | Reproducibility of Results | 2 | 2019 | 2752 | 0.100 |
Why?
| | Ventricular Premature Complexes | 1 | 2012 | 26 | 0.100 |
Why?
| | Risk Factors | 4 | 2020 | 8606 | 0.100 |
Why?
| | Decision Making | 1 | 2017 | 761 | 0.090 |
Why?
| | Biopsy | 1 | 2015 | 1024 | 0.090 |
Why?
| | Natriuretic Peptides | 1 | 2011 | 8 | 0.090 |
Why?
| | Gene Expression Regulation | 3 | 2020 | 2293 | 0.090 |
Why?
| | Kaplan-Meier Estimate | 2 | 2010 | 809 | 0.090 |
Why?
| | Neurotransmitter Agents | 1 | 2011 | 74 | 0.090 |
Why?
| | Exercise | 1 | 2020 | 1617 | 0.090 |
Why?
| | Stroke | 1 | 2019 | 1016 | 0.090 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1682 | 0.090 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2022 | 152 | 0.090 |
Why?
| | Connectin | 2 | 2022 | 30 | 0.090 |
Why?
| | Endpoint Determination | 2 | 2020 | 68 | 0.090 |
Why?
| | Anticoagulants | 1 | 2014 | 548 | 0.090 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2011 | 126 | 0.090 |
Why?
| | Task Performance and Analysis | 1 | 2011 | 160 | 0.090 |
Why?
| | Comorbidity | 2 | 2020 | 1443 | 0.080 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 180 | 0.080 |
Why?
| | Extracellular Matrix Proteins | 1 | 2011 | 125 | 0.080 |
Why?
| | Pericardial Effusion | 1 | 2010 | 21 | 0.080 |
Why?
| | Disease Models, Animal | 4 | 2022 | 3470 | 0.080 |
Why?
| | DNA | 1 | 2016 | 1331 | 0.080 |
Why?
| | Heart Septum | 1 | 2009 | 28 | 0.080 |
Why?
| | Cells, Cultured | 3 | 2022 | 3802 | 0.080 |
Why?
| | Myocardial Revascularization | 1 | 2009 | 67 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1168 | 0.080 |
Why?
| | Ultrasonography | 1 | 2012 | 632 | 0.080 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2011 | 286 | 0.080 |
Why?
| | Transcription Factors | 1 | 2016 | 1497 | 0.080 |
Why?
| | Europe | 2 | 2020 | 331 | 0.080 |
Why?
| | Coronary Circulation | 1 | 2008 | 131 | 0.070 |
Why?
| | Syndrome | 1 | 2008 | 328 | 0.070 |
Why?
| | Body Temperature | 1 | 2007 | 176 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 662 | 0.070 |
Why?
| | Cardiac Catheterization | 2 | 2020 | 540 | 0.070 |
Why?
| | Blood Flow Velocity | 1 | 2008 | 374 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 252 | 0.070 |
Why?
| | Delivery of Health Care | 2 | 2023 | 828 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 3 | 2020 | 2077 | 0.070 |
Why?
| | Survivors | 1 | 2009 | 414 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2022 | 2523 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2009 | 348 | 0.060 |
Why?
| | Clinical Protocols | 2 | 2017 | 231 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2009 | 1378 | 0.060 |
Why?
| | Education, Medical, Graduate | 1 | 2009 | 366 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2020 | 4400 | 0.050 |
Why?
| | Genotype | 2 | 2020 | 1733 | 0.050 |
Why?
| | Cytokines | 1 | 2011 | 1795 | 0.050 |
Why?
| | Sarcoplasmic Reticulum | 1 | 2023 | 43 | 0.050 |
Why?
| | Troponin | 1 | 2023 | 44 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1176 | 0.050 |
Why?
| | Travel | 1 | 2023 | 117 | 0.050 |
Why?
| | Adolescent | 4 | 2019 | 17724 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2018 | 2139 | 0.050 |
Why?
| | Histone Deacetylase 6 | 1 | 2022 | 19 | 0.050 |
Why?
| | Signal Transduction | 3 | 2021 | 4439 | 0.050 |
Why?
| | Disulfides | 1 | 2022 | 90 | 0.050 |
Why?
| | Death, Sudden, Cardiac | 1 | 2023 | 160 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2022 | 144 | 0.050 |
Why?
| | Catecholamines | 1 | 2022 | 92 | 0.050 |
Why?
| | RNA Splicing Factors | 1 | 2022 | 49 | 0.050 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2002 | 41 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2022 | 4617 | 0.050 |
Why?
| | Prevalence | 2 | 2018 | 2244 | 0.050 |
Why?
| | Calcium Channels | 1 | 2022 | 144 | 0.050 |
Why?
| | Graft Survival | 1 | 2023 | 441 | 0.050 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2022 | 306 | 0.050 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2002 | 130 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2022 | 324 | 0.050 |
Why?
| | Valsalva Maneuver | 1 | 2021 | 10 | 0.050 |
Why?
| | Anaerobic Threshold | 1 | 2021 | 21 | 0.050 |
Why?
| | Chronic Disease | 2 | 2017 | 1570 | 0.050 |
Why?
| | Phenylephrine | 1 | 2021 | 71 | 0.050 |
Why?
| | Cardiomegaly | 1 | 2022 | 158 | 0.050 |
Why?
| | Diagnostic Techniques, Cardiovascular | 1 | 2020 | 11 | 0.050 |
Why?
| | Pharmacogenomic Testing | 1 | 2021 | 53 | 0.040 |
Why?
| | Seizures | 1 | 2023 | 335 | 0.040 |
Why?
| | Culture Media | 1 | 2021 | 151 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2023 | 585 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2023 | 224 | 0.040 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2021 | 109 | 0.040 |
Why?
| | Cytomegalovirus | 1 | 2021 | 140 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2022 | 426 | 0.040 |
Why?
| | Prealbumin | 1 | 2020 | 22 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 516 | 0.040 |
Why?
| | Heart Function Tests | 1 | 2020 | 59 | 0.040 |
Why?
| | Heart Valve Diseases | 1 | 2002 | 161 | 0.040 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2020 | 42 | 0.040 |
Why?
| | Electric Countershock | 1 | 2020 | 104 | 0.040 |
Why?
| | Norepinephrine | 1 | 2021 | 197 | 0.040 |
Why?
| | Acylation | 1 | 2019 | 28 | 0.040 |
Why?
| | Internship and Residency | 1 | 2009 | 920 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2022 | 382 | 0.040 |
Why?
| | Program Evaluation | 2 | 2017 | 821 | 0.040 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 61 | 0.040 |
Why?
| | Gene Silencing | 1 | 2020 | 169 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2020 | 92 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 174 | 0.040 |
Why?
| | Methylation | 1 | 2019 | 208 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 251 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2020 | 448 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2021 | 568 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 314 | 0.040 |
Why?
| | Zebrafish | 1 | 2022 | 407 | 0.040 |
Why?
| | Mice, Knockout, ApoE | 1 | 2018 | 8 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 307 | 0.040 |
Why?
| | Fibroblasts | 1 | 2022 | 827 | 0.040 |
Why?
| | Fatty Acids | 1 | 2021 | 380 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 4593 | 0.040 |
Why?
| | Lysine | 1 | 2019 | 240 | 0.040 |
Why?
| | Hydroxamic Acids | 1 | 2018 | 80 | 0.040 |
Why?
| | Collagen | 1 | 2020 | 411 | 0.040 |
Why?
| | Myosins | 1 | 2018 | 123 | 0.040 |
Why?
| | Tissue Donors | 1 | 2019 | 313 | 0.040 |
Why?
| | Alleles | 1 | 2020 | 781 | 0.040 |
Why?
| | Hyperplasia | 1 | 2018 | 163 | 0.040 |
Why?
| | Activities of Daily Living | 1 | 2020 | 348 | 0.040 |
Why?
| | Fluorine Radioisotopes | 1 | 2017 | 10 | 0.030 |
Why?
| | Autoradiography | 1 | 2017 | 69 | 0.030 |
Why?
| | Circadian Rhythm | 1 | 2020 | 347 | 0.030 |
Why?
| | Diphenoxylate | 1 | 2016 | 5 | 0.030 |
Why?
| | Atropine | 1 | 2016 | 25 | 0.030 |
Why?
| | Loperamide | 1 | 2016 | 10 | 0.030 |
Why?
| | Antidiarrheals | 1 | 2016 | 15 | 0.030 |
Why?
| | Papio | 1 | 2017 | 96 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 372 | 0.030 |
Why?
| | Organ Culture Techniques | 1 | 2017 | 140 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 632 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2020 | 3013 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 737 | 0.030 |
Why?
| | Transcription Initiation Site | 1 | 2016 | 39 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 554 | 0.030 |
Why?
| | Transcription Elongation, Genetic | 1 | 2016 | 20 | 0.030 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2018 | 197 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2017 | 158 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2016 | 60 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2021 | 777 | 0.030 |
Why?
| | Mental Health | 1 | 2021 | 559 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 285 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2016 | 129 | 0.030 |
Why?
| | Actins | 1 | 2018 | 373 | 0.030 |
Why?
| | Acetylation | 1 | 2016 | 208 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2018 | 716 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 1783 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 435 | 0.030 |
Why?
| | Self-Management | 1 | 2017 | 126 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2581 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1203 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2018 | 407 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2020 | 1925 | 0.030 |
Why?
| | Factor X | 1 | 2014 | 25 | 0.030 |
Why?
| | Mass Screening | 1 | 2021 | 978 | 0.030 |
Why?
| | Child, Preschool | 2 | 2019 | 9093 | 0.030 |
Why?
| | Proteomics | 1 | 2019 | 808 | 0.030 |
Why?
| | Reoperation | 1 | 2016 | 505 | 0.030 |
Why?
| | Action Potentials | 1 | 2017 | 402 | 0.030 |
Why?
| | Models, Biological | 1 | 2021 | 1589 | 0.030 |
Why?
| | Cobalt | 1 | 2014 | 43 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 984 | 0.030 |
Why?
| | Self Report | 1 | 2017 | 696 | 0.030 |
Why?
| | Warfarin | 1 | 2014 | 136 | 0.030 |
Why?
| | RNA Polymerase II | 1 | 2016 | 283 | 0.030 |
Why?
| | Amino Acids, Aromatic | 1 | 2013 | 8 | 0.030 |
Why?
| | Depression | 1 | 2021 | 1131 | 0.030 |
Why?
| | Algorithms | 1 | 2020 | 1462 | 0.030 |
Why?
| | Heparin | 1 | 2014 | 225 | 0.030 |
Why?
| | Creatine | 1 | 2013 | 51 | 0.030 |
Why?
| | Chromatin | 1 | 2016 | 418 | 0.030 |
Why?
| | Alanine | 1 | 2013 | 104 | 0.030 |
Why?
| | Glutamine | 1 | 2013 | 90 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 543 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2020 | 2507 | 0.030 |
Why?
| | Antibodies | 1 | 2014 | 354 | 0.030 |
Why?
| | Medication Adherence | 1 | 2017 | 530 | 0.030 |
Why?
| | Dyspnea | 1 | 2014 | 211 | 0.020 |
Why?
| | Phenotype | 1 | 2020 | 2754 | 0.020 |
Why?
| | Fatigue | 1 | 2014 | 292 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 829 | 0.020 |
Why?
| | Lactic Acid | 1 | 2013 | 269 | 0.020 |
Why?
| | Patient Discharge | 1 | 2016 | 770 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 1705 | 0.020 |
Why?
| | Child | 2 | 2019 | 18340 | 0.020 |
Why?
| | Catheter Ablation | 1 | 2012 | 288 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 2875 | 0.020 |
Why?
| | Glucose | 1 | 2013 | 894 | 0.020 |
Why?
| | Focus Groups | 1 | 2009 | 379 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 6296 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2009 | 605 | 0.020 |
Why?
| | Infant | 1 | 2015 | 7922 | 0.010 |
Why?
| | Clinical Competence | 1 | 2009 | 882 | 0.010 |
Why?
| | Observer Variation | 1 | 2002 | 298 | 0.010 |
Why?
|
|
Ambardekar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|